Does the media favor SEPN or DMAC?

In the previous week, Septerna had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Septerna and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Septerna's score of 1.09 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or DMAC more profitable?

Generate Biomedicines' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media refer more to GENB or DMAC?

In the previous week, Generate Biomedicines had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Generate Biomedicines and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Generate Biomedicines' score of 0.47 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DMAC or NVAX?

In the previous week, Novavax had 13 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 15 mentions for Novavax and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Novavax's score of -0.07 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media refer more to DMAC or NTLA?

In the previous week, Intellia Therapeutics had 9 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 11 mentions for Intellia Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Intellia Therapeutics' score of 0.69 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DMAC or STOK?

In the previous week, Stoke Therapeutics had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Stoke Therapeutics' score of 0.54 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DiaMedica Therapeutics (DMAC) Competitors

$7.71 -0.11 (-1.41%)

As of 12:45 PM Eastern

Compare

DMAC vs. SEPN, GENB, NVAX, NTLA, and STOK

Should you buy DiaMedica Therapeutics stock or one of its competitors? DiaMedica Therapeutics's main competitors and comparable companies include Septerna (SEPN), Generate Biomedicines (GENB), Novavax (NVAX), Intellia Therapeutics (NTLA), and Stoke Therapeutics (STOK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DiaMedica Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Septerna presently has a consensus target price of $52.44, indicating a potential upside of 44.00%. DiaMedica Therapeutics has a consensus target price of $12.00, indicating a potential upside of 53.45%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DiaMedica Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Septerna had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Septerna and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Septerna's score of 1.09 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	37.00	-$48.88M	-$0.54	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Summary

Septerna beats DiaMedica Therapeutics on 10 of the 16 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

In the previous week, Generate Biomedicines had 6 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 8 mentions for Generate Biomedicines and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Generate Biomedicines' score of 0.47 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines currently has a consensus price target of $26.40, suggesting a potential upside of 115.33%. DiaMedica Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 53.45%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Generate Biomedicines is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Generate Biomedicines' return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

DiaMedica Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	49.34	-$203.15M	-$1.59	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Summary

Generate Biomedicines beats DiaMedica Therapeutics on 7 of the 12 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Novavax?

DiaMedica Therapeutics (NASDAQ:DMAC) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

DiaMedica Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Novavax	-59.87%	-14.82%	-13.35%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Novavax has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market.

In the previous week, Novavax had 13 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 15 mentions for Novavax and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Novavax's score of -0.07 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Novavax has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A

DiaMedica Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 53.45%. Novavax has a consensus target price of $14.00, suggesting a potential upside of 9.20%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe DiaMedica Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Novavax beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Intellia Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

DiaMedica Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

DiaMedica Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 9 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 11 mentions for Intellia Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Intellia Therapeutics' score of 0.69 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DiaMedica Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 53.45%. Intellia Therapeutics has a consensus price target of $20.72, suggesting a potential upside of 73.95%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26

DiaMedica Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Intellia Therapeutics	$67.67M	24.66	-$412.69M	-$3.36	N/A

Summary

Intellia Therapeutics beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Stoke Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DiaMedica Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 53.45%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 96.67%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

DiaMedica Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

DiaMedica Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Stoke Therapeutics' score of 0.54 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Stoke Therapeutics	$184.42M	7.87	-$6.89M	-$3.34	N/A

Summary

Stoke Therapeutics beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$415.53M	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-10.70	12.99	275.44	25.42
Price / Sales	N/A	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	7.14	16.88	10.66	5.96
Net Income	-$32.77M	-$22.65M	$3.50B	$380.62M
7 Day Performance	-3.50%	-5.64%	-3.65%	-3.75%
1 Month Performance	17.71%	-13.53%	-8.06%	-6.62%
1 Year Performance	12.55%	6.87%	2.58%	-4.38%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.9515 of 5 stars	$7.71 -1.4%	$12.00 +55.6%	+10.8%	$415.53M	N/A	N/A	35	Positive News
SEPN Septerna	2.55 of 5 stars	$37.71 -0.9%	$52.44 +39.1%	+51.2%	$1.76B	$45.95M	N/A	130
GENB Generate Biomedicines	2.2565 of 5 stars	$13.69 -0.8%	$26.40 +92.8%	N/A	$1.76B	$31.89M	N/A	312	News Coverage Gap Up
NVAX Novavax	1.7433 of 5 stars	$10.46 -1.3%	$14.00 +33.8%	+48.7%	$1.73B	$1.12B	N/A	749
NTLA Intellia Therapeutics	3.3296 of 5 stars	$12.26 +1.2%	$20.98 +71.1%	-49.9%	$1.72B	$67.67M	N/A	377	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. SEPN, GENB, NVAX, NTLA, and STOK

How does DiaMedica Therapeutics compare to Septerna?

Summary

How does DiaMedica Therapeutics compare to Generate Biomedicines?

Summary

How does DiaMedica Therapeutics compare to Novavax?

Summary

How does DiaMedica Therapeutics compare to Intellia Therapeutics?

Summary

How does DiaMedica Therapeutics compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. SEPN, GENB, NVAX, NTLA, and STOK

How does DiaMedica Therapeutics compare to Septerna?

Do analysts prefer SEPN or DMAC?

Is SEPN or DMAC more profitable?

Do institutionals and insiders believe in SEPN or DMAC?

Does the media favor SEPN or DMAC?

Which has better valuation and earnings, SEPN or DMAC?

Which has more volatility and risk, SEPN or DMAC?

Summary

How does DiaMedica Therapeutics compare to Generate Biomedicines?

Does the media refer more to GENB or DMAC?

Do analysts recommend GENB or DMAC?

Do insiders and institutionals have more ownership in GENB or DMAC?

Is GENB or DMAC more profitable?

Which has better earnings & valuation, GENB or DMAC?

Summary

How does DiaMedica Therapeutics compare to Novavax?

Is DMAC or NVAX more profitable?

Do institutionals & insiders hold more shares of DMAC or NVAX?

Which has more volatility and risk, DMAC or NVAX?

Does the media refer more to DMAC or NVAX?

Which has preferable valuation & earnings, DMAC or NVAX?

Do analysts recommend DMAC or NVAX?

Summary

How does DiaMedica Therapeutics compare to Intellia Therapeutics?

Is DMAC or NTLA more profitable?

Which has more risk & volatility, DMAC or NTLA?

Does the media refer more to DMAC or NTLA?

Do institutionals and insiders hold more shares of DMAC or NTLA?

Do analysts recommend DMAC or NTLA?

Which has better valuation and earnings, DMAC or NTLA?

Summary

How does DiaMedica Therapeutics compare to Stoke Therapeutics?

Do insiders and institutionals hold more shares of DMAC or STOK?

Do analysts recommend DMAC or STOK?

Is DMAC or STOK more profitable?

Which has more risk and volatility, DMAC or STOK?

Does the media refer more to DMAC or STOK?

Which has higher earnings & valuation, DMAC or STOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools